This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A compound of Formula I



I

~~a prodrug of said compound,~~ or a pharmaceutically acceptable salt of said compound ~~or prodrug~~;

wherein R_1 is a) -(C_1-C_6)alkyl optionally substituted with -CF_3, b) -C≡C-CH_3, c) -C≡C-Cl, d) -C≡C-CF_3, e) -CH_2O(C_1-C_4)alkyl optionally substituted with -CF_3 or f) -CF_3;

R_2 is a) -(C_1-C_5)alkyl, b) -(C_2-C_5)alkenyl or c) -phenyl optionally substituted with one of the following: -OH, -NR_9-C(O)-(C_2-C_4)alkyl, -CN, -Z-het, -O-(C_1-C_3)alkyl-C(O)-NR_9R_{10}, -NR_9-Z-C(O)-NR_9R_{10}, -Z-NR_9-SO_2-R_{10}, -NR_9-SO_2-het, -O-C(O)-(C_1-C_4)alkyl or -O-SO_2-(C_1-C_4)alkyl;

Z for each occurrence is independently -(C_0-C_4)alkyl;

R_3 is a) -hydrogen, b) -(C_1-C_6)alkyl optionally substituted with one to three halo, c) -(C_2-C_6)alkenyl or d) -(C_2-C_6)alkynyl optionally substituted with one to three halo;

R_4 is a) -hydrogen~~,~~ or b) -(C_2-C_5)alkyl-NR_5R_6 ~~or c) (C_0-C_5)alkyl-het; or R_3 and R_4 are taken together with N to form het~~;

R_5 and R_6 are each independently a) hydrogen or b) -(C_1-C_3)alkyl;

het is an optionally substituted 5-, 6- or 7-membered saturated, partially saturated or unsaturated heterocyclic ring containing from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with one to four R_7; provided that het is other than pyridinyl, imidazolyl or tetrazolyl;

R_7 is a) -(C_1-C_6)alkyl optionally substituted with one to three R_8, b) –Z-NR_9R_{10} or c) –Z-C(O)-NR_9R_{10};

R_8 for each occurrence is independently a) halo, b) –OH, c) oxo or d) -O(C_1-C_6)alkyl;

R_9 and R_{10} for each occurrence are independently a) -H or b) -(C_1-C_3)alkyl;

or R_9 and R_{10} are taken together with N to form het;

provided that:

1) when R_1 is –C≡C-CH_3, R_2 is phenyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$, or –$(CH_2)_3$-$N(CH_3)_2$, ~~–$(CH_2)_2$-pyrrolidinyl optionally substituted with methyl, –$(CH_2)_3$-pyrrolidinyl or –$(CH_2)_2$-morpholinyl~~;

~~2) when R_1 is –C≡C-CH_3, R_2 is –CH_2-CH=CH_2 and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-pyrrolidinyl;~~

A1 2) ~~3)~~ when R_1 is –C≡C-CH_3, R_2 is propyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$ ~~or –$(CH_2)_2$-pyrrolidinyl~~; and

3) ~~4)~~ when R_1 is –C≡C-CH_3, R_2 is butyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-$N(CH_3)_2$, ~~–$(CH_2)_2$-pyrrolidinyl or –$(CH_2)_2$-morpholinyl; and~~

~~5) when R_1 is –C≡C-CH_3, R_2 is pentyl and R_3 is hydrogen, then R_4 is other than –$(CH_2)_2$-morpholinyl or –$(CH_2)_2$-pyrrolidinyl.~~

2. (currently amended) A compound of claim 1 of Formula II



II

~~a prodrug of said compound~~ or a pharmaceutically acceptable salt of said compound ~~or prodrug~~;

wherein R_1 is a) -(C_1-C_6)alkyl optionally substituted with -CF_3, b) -C≡C-CH_3, c) –CF_3 or d) –$CH_2O(C_2$-C_4)alkyl.

3. (original) A compound of claim 2 wherein R_1 is a) –$CH_2CH_2CH_3$, b) -C≡C-CH_3 or c) –CF_3.

4. (original) A compound of claim 3

wherein R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

5. (original) A compound of claim 4

wherein R_3 is a) methyl, b) ethyl, c) propyl or d) isopropyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

6. (original) A compound of claim 5

wherein R_3 is a) methyl or b) ethyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each methyl.

7-11. (canceled).

12. (original) A compound of claim 1

wherein R_1 is a) $-CH_2CH_2CH_3$, b) $-C\equiv C-CH_3$ or c) $-CF_3$;

R_2 is a) -(C_1-C_5)alkyl or b) -(C_2-C_5)alkenyl;

R_3 is a) hydrogen, b) methyl, c) ethyl, d) propyl or e) isopropyl;

R_4 is -(C_2-C_3)alkyl-NR_5R_6;

R_5 and R_6 are each independently a) methyl, b) ethyl, c) propyl or d) isopropyl.

13. (original) A compound of claim 12

wherein R_2 is a) methyl, b) ethyl, c) propyl, d) ethenyl, e) propenyl or f) butenyl;

R_3 is a) hydrogen, b) methyl or c) ethyl,

R_5 and R_6 are each independently a) methyl or b) ethyl.

14-17. (canceled).

18. (original) A compound of claim 1 wherein in Formula I $-CH_2-R_2$ is ethenyl or ethynyl.

19. (original) A compound of claim 4 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [3-(diethylamino)propyl]-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-

octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

11 20. (original) A compound of claim 6 selected from the group consisting of:

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester;

carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester;

carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester; and

carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4b*S*,7*R*,8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester.

21-23. (canceled).

A1 12 24. (original) A compound of claim 13 selected from the group consisting of:

carbamic acid, (3-dimethylaminopropyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)methyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester;

carbamic acid, (2-dimethylaminoethyl)ethyl-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester; and

carbamic acid, (2-dimethylaminoethyl)-, (4b*S*, 7*R*, 8a*R*)-4b,5,6,7,8,8a,9,10-octahydro-4b-ethyl-7-hydroxy-7-prop-1-ynyl-phenanthren-2-yl ester.

25-26. (canceled)

13 27. (currently amended) A method for the treatment of a glucocorticoid receptor-mediated disease or condition which is selected from obesity, diabetes, depression, anxiety and neurodegeneration in a mammal, which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1, ~~a prodrug thereof, or~~ a pharmaceutically acceptable salt of said compound ~~or prodrug~~.

28. (canceled)

14 29. (currently amended) The method of claim ~~28~~ 27 wherein the condition is obesity.

30-41. (canceled)